Fragmentomics company whose FirstLook Lung blood test aims to raise lung-cancer screening uptake; first randomised clinical-utility data in 2026.
FirstLook Lung (launched 2023) analyses cfDNA fragmentation patterns to identify who should proceed to low-dose CT. The L301 FIRSTLUNG cluster-randomised trial (NCT06145750) was presented as a late-breaker at ATS 2026; AACR 2026 showed whole-genome cfDNA advances in detection and monitoring. Johns Hopkins spin-out.
Shares Push residual disease detection a hundredfold deeper with whole-genome methods, Liquid biopsy (ctDNA).
Shares Johns Hopkins Hospital / Sidney Kimmel Comprehensive Cancer Center, ctDNA tests roadmap: from a curiosity in plasma to blood tests that decide treatment, Liquid biopsy (ctDNA).
Shares ctDNA tests roadmap: from a curiosity in plasma to blood tests that decide treatment, Liquid biopsy (ctDNA), Non-small-cell lung cancer.
Shares ctDNA tests roadmap: from a curiosity in plasma to blood tests that decide treatment, The hardest cancers are found late, Liquid biopsy (ctDNA), Non-small-cell lung cancer.
Shares ctDNA tests roadmap: from a curiosity in plasma to blood tests that decide treatment, Liquid biopsy (ctDNA), Non-small-cell lung cancer.
Shares ctDNA tests roadmap: from a curiosity in plasma to blood tests that decide treatment, Liquid biopsy (ctDNA).
Shares ctDNA tests roadmap: from a curiosity in plasma to blood tests that decide treatment, Liquid biopsy (ctDNA).
Shares ctDNA tests roadmap: from a curiosity in plasma to blood tests that decide treatment, Liquid biopsy (ctDNA).
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/